

Enhanced Efficacy

NOW you hold ~~the~~ power
to fight for your patients

more



The first antimicrobial IV connector

Now kills at least 99.99% of 6 common pathogens known to cause catheter-related bloodstream infections (CR-BSIs)^{1*}

*These in vitro test results of typical devices have not been shown to correlate with a reduction in infections.

To learn more about the new V-Link device or any of our other products, contact your Baxter representative or the Baxter Product Information Center at 1-800-933-0303, or visit www.baxter.com.

The antimicrobial agent is not intended to be used as a treatment for existing infections.
Rx only.

For safe and proper use of this device, please refer to the complete instructions for use.

Options at work.



MEDICATION DELIVERY

Baxter

¹Data on file, Baxter Healthcare Corporation.

Baxter, Committed to a Safer Healthcare Environment, V-Link, and VitalShield are trademarks of Baxter International Inc. Baxter Healthcare Corporation, Route 120 and Wilson Road, Round Lake, IL 60073 www.baxter.com 213399 09/08

INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY

VOLUME 29, NUMBER 10

OCTOBER 2008

CONTENTS CONTINUED FROM COVER

- 963 Efficacy of Adding 2% (w/v) Chlorhexidine Gluconate to 70% (v/v) Isopropyl Alcohol for Skin Disinfection Prior to Peripheral Venous Cannulation** • Heather Small, MSc; Debra Adams, PhD; Anna L. Casey, PhD; Cynthia T. Crosby, BS; Peter A. Lambert, DSc; Thomas Elliott, FRMS, PhD, DSc, MRCP, FRCPath
- 966 Use of Active Surveillance Cultures to Detect Asymptomatic Colonization With Carbapenem-Resistant *Klebsiella pneumoniae* in Intensive Care Unit Patients** • David Calfee, MD, MS; Stephen G. Jenkins, PhD
- 969 Development of a Prediction Rule for Methicillin-Resistant *Staphylococcus aureus* and Vancomycin-Resistant *Enterococcus* Carriage in a Veterans Affairs Medical Center Population** • Stefan Riedel, MD; Diana Von Stein, MPH; Kelly Richardson, PhD; Joann Page, BSN; Sara Miller, BSN; Patricia Winokur, MD; Daniel Diekema, MD
- 972 Clinical Utility of Infection Control Documentation of Prior Methicillin-Resistant *Staphylococcus aureus* Colonization or Infection for Optimization of Empirical Antibiotic Therapy** • Marin L. Schweizer, BS; Jon P. Furuno, PhD; Anthony D. Harris, MD, MPH; Jessina C. McGregor, PhD; Kerri A. Thom, MD; Jennifer K. Johnson, PhD; Michelle D. Shardell, PhD; Eli N. Perencevich, MD, MS
- 975 Coadministration of Oral Levofloxacin With Agents That Impair Absorption: Impact on Antibiotic Resistance** • Keira A. Cohen, BS; Ebbing Lautenbach, MD, MPD, MSCE; Mark G. Weiner, MD; Marie Synnestvedt, MSEd; Leanne B. Gasink, MD, MSCE
- 978 Secular Trends in Candidemia-Related Hospitalization in the United States, 2000–2005** • Marya D. Zilberberg, MD; Andrew F. Shorr, MD, MPH; Marin H. Kollef, MD
- 981 Bacteriology of Blood, Wound, and Sputum Cultures from Non-US Casualties Treated in a Combat Support Hospital in Iraq** • Kimberly A. Moran, MD; Clinton K. Murray, MD; Edwin L. Anderson, MD

LETTERS TO THE EDITOR

- 985 Surveillance of Central Venous Catheter-Associated Bloodstream Infection in a Scottish Hematology Unit** • Ann Graham, RN; William J. Olver, FRCPath
- 986 Reply to Graham and Olver** • Leon J. Worth, MBBS, FRACP; James Black, MBBS, PhD; Monica A. Slavin, MBBS, FRACP
- 987 Has the Time Come to Recommend the Use of Alcohol-Based Hand Rub to Hospitalized Patients?** • Viktorija Tomic, MD, MSc; Viktor Ursic, BSc; Katja Seme, MD, PhD
- 989 Trends in *Stenotrophomonas maltophilia* Bloodstream Infection in Relation to Usage Density of Cephalosporins and Carbapenems During 7 Years** • Jorge G. Paez, MD; Anna S. Levin, PhD; Mariusa Bassi, Laura B. Gomez; Satiko Gobara; Fernanda Spadão; Isabel Oshiro; Silvia Figueiredo Costa, PhD
- 990 Clinical Features and Treatment Outcomes of Infections Caused by *Sphingomonas paucimobilis*** • Hae Suk Cheong, MD; Yu Mi Wi, MD; Soo Youn Moon, MD; Cheol-In Kang, MD; Jun Seong Son, MD; Kwan Soo Ko, PhD; Doo Ryeon Chung, MD; Nam Yong Lee, MD; Jae-Hoon Song, MD; Kyong Ran Peck, MD, PhD
- 993 Surveillance for Mupirocin Resistance Among Methicillin-Resistant *Staphylococcus aureus* Clinical Isolates** • Kanokporn Mongkolrattanothai, MD; Peggy Mankin, BS, MA; Venkedesh Raju, MD; Barry Gray, MD

FIND THE MICROBE THAT COULD COST THIS PATIENT HER LIFE.

80% of the bacteria that cause infections reside in the first five layers of the patient's own skin.¹ That's why there's ChloraPrep®. ChloraPrep combines the CDC-recommended formulation of 2% CHG with innovative, "hands-off" applicators to provide a more effective system for helping reduce infections associated with skin bacteria. ChloraPrep is fast-acting on a broad spectrum of bacteria, including MRSA, and inhibits bacterial growth for at least 48 hours.^{2,3} Help stop infection from the start with ChloraPrep.

- **PERSISTENT** antimicrobial activity inhibits the growth of bacteria for at least 48 hours^{2,3}
- **PROVEN** in 33 published studies as best practice for helping reduce the risk of infection
- **RECOMMENDED** use of 2% CHG formulation in at least 10 evidence-based guidelines, including the CDC, SCAI and IHI

REFERENCES 1. Brown E, Wenzel RP, Hendley JO. Exploration of the microbial anatomy of normal human skin by using plasmid profiles of coagulase-negative staphylococci: search for the reservoir of resident skin flora. *J Infect Dis.* 1989;160(4):644-650. 2. Garcia R, Mulberry G, Brady A, Hibbard JS. Comparison of ChloraPrep and Betadine as preoperative skin preparation antiseptics. Poster presented at 40th Annual Meeting of the Infectious Diseases Society of America; October 25, 2002; Chicago, Ill. 3. Data on file. Cardinal Health, Inc.



ChloraPrep®
Patient Preoperative Skin Preparation
2% Chlorhexidine Gluconate (CHG)
& 70% Isopropyl Alcohol (IPA)

chloraprep.com | 800-523-0502

©2008 Cardinal Health, Inc. All rights reserved. ChloraPrep is a registered trademark of Cardinal Health, Inc. or one of its subsidiaries. ADV-SBC1008

